NO793412L - Fremgangsmaate for fremstilling av overfoeringsfaktor mot patogene antigener - Google Patents
Fremgangsmaate for fremstilling av overfoeringsfaktor mot patogene antigenerInfo
- Publication number
- NO793412L NO793412L NO793412A NO793412A NO793412L NO 793412 L NO793412 L NO 793412L NO 793412 A NO793412 A NO 793412A NO 793412 A NO793412 A NO 793412A NO 793412 L NO793412 L NO 793412L
- Authority
- NO
- Norway
- Prior art keywords
- transfer factor
- humans
- stated
- antigen
- molecular weight
- Prior art date
Links
- 108010074506 Transfer Factor Proteins 0.000 title claims description 64
- 239000000427 antigen Substances 0.000 title claims description 22
- 102000036639 antigens Human genes 0.000 title claims description 22
- 108091007433 antigens Proteins 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 14
- 230000001717 pathogenic effect Effects 0.000 title claims description 14
- 244000052769 pathogen Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 210000000265 leukocyte Anatomy 0.000 claims description 24
- 241000282412 Homo Species 0.000 claims description 19
- 241000282414 Homo sapiens Species 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 18
- 238000000502 dialysis Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 241000288906 Primates Species 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000007911 parenteral administration Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 8
- 241000282887 Suidae Species 0.000 description 7
- 201000008968 osteosarcoma Diseases 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000007969 cellular immunity Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010061495 Rickettsiosis Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK475278 | 1978-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO793412L true NO793412L (no) | 1980-05-06 |
Family
ID=8136351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO793412A NO793412L (no) | 1978-10-25 | 1979-10-24 | Fremgangsmaate for fremstilling av overfoeringsfaktor mot patogene antigener |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0010738A1 (ja) |
| JP (1) | JPS56500015A (ja) |
| FI (1) | FI793338A (ja) |
| NO (1) | NO793412L (ja) |
| WO (1) | WO1980000790A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI78483C (fi) * | 1980-05-14 | 1989-08-10 | A Arthur Gottlieb | Rening av modulatorer foer immunsystem. |
| US4468379A (en) * | 1982-05-06 | 1984-08-28 | Endeavor Corp. | Leukocyte extracts for affecting the immune system |
| JPS5967226A (ja) * | 1982-07-20 | 1984-04-16 | デイミトリ・ビザ | ウイルス感染処置に使用する転移因子 |
| GB8614733D0 (en) * | 1986-06-17 | 1986-07-23 | Lefesvre A | Aids treatment |
| MX9504215A (es) * | 1995-10-05 | 1997-04-30 | Inst Politecnico Nacional | Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica. |
| AU7780598A (en) * | 1997-06-05 | 1998-12-21 | Neuroimmuno Therapeutics Research Foundation | Pharmaceutical composition containing transfer factor for treatment of inflam matory bowel disease and regressive behavioural disorder |
| WO2000003733A1 (en) * | 1998-07-16 | 2000-01-27 | Vincent Marinkovich | Methods and compositions for cancer treatment |
| MXPA02002171A (es) * | 2002-02-28 | 2002-12-09 | Antonio Calzada Nova Luis | Extracto de leucocitos dializado en la elaboracion de un farmaco para el tratamiento de enfermedades infecciosas en animales. |
| CZ299296B6 (cs) * | 2006-06-13 | 2008-06-11 | Sevapharma A.S. | Lécivo transfer faktor - zpusob výroby a použití |
| CN103599534B (zh) * | 2013-10-24 | 2015-07-08 | 福州派生特生物科技有限公司 | 禽疫苗特异性猪脾脏转移因子的制备方法及用途 |
| CN103892166B (zh) * | 2014-04-11 | 2016-11-23 | 江西德泰医药生物技术有限公司 | 一种多肽因子和中草药提取物制备保健食品的方法 |
| CN109157543A (zh) * | 2018-09-30 | 2019-01-08 | 派生特（福州）生物科技有限公司 | 一种注射用猪胎盘转移因子及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617865A1 (de) * | 1966-03-12 | 1971-09-02 | Karl Dr Med Theurer | Verfahren zur Herstellung von Arzneimitteln gegen Krebs |
| US3991182A (en) * | 1971-10-19 | 1976-11-09 | The Regents Of The University Of California | Transfer factor |
| DE2164565A1 (de) * | 1971-12-24 | 1973-06-28 | Walter Prof Dr Hartenbach | Verfahren zur gewinnung von krebshemmenden stoffen |
| US4001080A (en) * | 1972-10-20 | 1977-01-04 | Piktor Limited | Production of immunological materials |
| US4132776A (en) * | 1978-02-15 | 1979-01-02 | University Patents, Inc. | Delivery of immunologically active components of transfer factor |
-
1979
- 1979-10-24 NO NO793412A patent/NO793412L/no unknown
- 1979-10-24 WO PCT/DK1979/000039 patent/WO1980000790A1/en unknown
- 1979-10-24 JP JP50192979A patent/JPS56500015A/ja active Pending
- 1979-10-25 FI FI793338A patent/FI793338A/fi not_active Application Discontinuation
- 1979-10-25 EP EP79104144A patent/EP0010738A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56500015A (ja) | 1981-01-08 |
| WO1980000790A1 (en) | 1980-05-01 |
| FI793338A (fi) | 1980-04-26 |
| EP0010738A1 (en) | 1980-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nachman et al. | Characterization of human platelet vascular permeability-enhancing activity | |
| US4002602A (en) | Ubiquitous immunopoietic polypeptide (UBIP) and methods | |
| Wong et al. | Immunosuppressive and immunostimulatory factors produced by malignant cells in vitro | |
| Brandes et al. | New approach to immunotherapy of melanoma | |
| Fangmann et al. | T cell recognition of donor major histocompatibility complex class Ipeptides during allograft rejection | |
| IL129211A (en) | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders | |
| CN101790382A (zh) | 独特型疫苗 | |
| US8404803B2 (en) | Cancer-associated antigen analogue peptides and uses thereof | |
| NO793412L (no) | Fremgangsmaate for fremstilling av overfoeringsfaktor mot patogene antigener | |
| CA1069822A (en) | Preparation of a hepatitis b immune globulin and use thereof as a prophylactic material | |
| CN106589133A (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
| Krementz et al. | Immunotherapy of malignant disease: The use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes | |
| Humphrey et al. | Immunologic response in patients with disseminated cancer | |
| CA1221028A (en) | Material for use in the treatment of spontaneous abortions | |
| Petrov et al. | Cell interactions in the immune response: Effect of humoral factor released from bone marrow cells on the quantity of mature antibody producers in culture of immune lymph node cells | |
| CN107028982B (zh) | 人胎盘乙型肝炎特异免疫活性多肽 | |
| US4009257A (en) | Preparation of immunosuppressive materials | |
| CN107325176B (zh) | 源于血红蛋白的免疫活性人胎盘多肽 | |
| US4001080A (en) | Production of immunological materials | |
| TW200404002A (en) | Treatment method achieved by using the lymphocytes derived from HLA matching donor-originating activated lymphocytes, formula having the lymphocytes as a main constituent thereof; method and preparation kit for manufacturing the formula | |
| EP0086475A2 (en) | A method of manufacturing anti-tumor substances | |
| CN110194800A (zh) | 一种融合蛋白、细胞外泌体和肿瘤疫苗及其应用 | |
| Shah et al. | Lymphocyte separation from blood | |
| JPH0296598A (ja) | リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤 | |
| Wong et al. | Immunomodulatory activities of whey fractions in efferent prefemoral lymph of sheep |